Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received approval from the National Medical Products Administration for the listing application of fumaric acid venlafaxine, which is primarily used to treat gastroesophageal reflux disease and eradicate Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical's approval for fumaric acid venlafaxine indicates that the raw material meets domestic drug registration requirements and has been approved for use in domestic formulations [1] - The approval of this raw material will further solidify the company's integrated development strategy of raw materials and formulations [1] - This development will expand the company's product range and accumulate valuable experience for future raw material drug applications [1]

Core Viewpoint - China Pharmaceutical announced that its wholly-owned subsidiary Tianfang Pharmaceutical received approval from the National Medical Products Administration for the listing application of fumaric acid volnorelaxin, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical has received the approval notice for fumaric acid volnorelaxin, indicating a significant advancement in its product pipeline [1] - The drug is intended for the treatment of gastroesophageal reflux disease and is used alongside antibiotics to eliminate Helicobacter pylori [1] - Additionally, Tianfang Pharmaceutical has obtained the European Pharmacopoeia suitability certificate for clindamycin phosphate, which is an antibiotic used for Gram-positive and anaerobic bacterial infections [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the market application of fumaric acid volnorasone, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical's approval for fumaric acid volnorasone indicates that the raw material meets domestic drug registration requirements and has been approved for use in domestic formulations [1] - The approval of this raw material will further solidify the company's integrated development strategy of raw materials and formulations [1] - This development will expand the company's product range and accumulate valuable experience for future raw material drug applications [1]

Core Viewpoint - China Pharmaceutical (600056) announced the approval of its subsidiary Tianfang Pharmaceutical's application for the active pharmaceutical ingredient Fumaric Acid Venlorasine by the National Medical Products Administration, indicating a significant advancement in its product pipeline [1] Group 1: Product Approvals - Tianfang Pharmaceutical received the approval notice for Fumaric Acid Venlorasine, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The company also obtained the European Pharmacopoeia suitability certificate for Clindamycin Phosphate, an antibiotic used for Gram-positive and anaerobic bacterial infections, from the European Medicines Agency [1]

Group 1 - The core point of the article is that Tianfang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of China National Pharmaceutical Group Corporation, has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnoreline [1] - The drug is primarily used for the treatment of gastroesophageal reflux disease and the eradication of Helicobacter pylori [1] - As of the date of the announcement, the total investment in the research and development of the raw materials and formulations for this project is approximately 11.36 million yuan [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Vonoprazan, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] Group 1 - The drug Fumaric Acid Vonoprazan has been approved for marketing, indicating a significant development for the company [1] - The approval is expected to enhance the company's product portfolio in the gastrointestinal treatment sector [1] - The drug's indication for use in combination with antibiotics highlights its potential in addressing common gastrointestinal infections [1]

Core Insights - The event highlighted the "2024 Annual Top 100 Enterprises in China's Pharmaceutical Industry," where Huabang Health (002004) was recognized as a leading pharmaceutical company again [1] - The ranking reflects the company's strong innovation drive and professional promotion capabilities within the pharmaceutical industry [1] Company Performance - Huabang Health has consistently focused on the health industry, enhancing its R&D investment, product quality control, and market channel expansion [1] - The company has improved its ranking since first being listed in 2020, showcasing its robust overall strength and industry leadership [1] Financial and Operational Highlights - In 2024, Huabang Health's medical business revenue showed steady growth, with bed utilization rates also improving [1] - The company placed significant emphasis on pharmaceutical R&D, achieving several milestones: four formulation products received market approval, one formulation product passed consistency evaluation, six raw material drug varieties and pharmaceutical excipients obtained A certification, and five raw material drug varieties received international certification [1] Product Development - Huabang Health is actively expanding into the dermatological product sector, launching two new functional skincare products to enhance its skin health product matrix [1] - The company aims to develop a comprehensive industry chain that integrates raw materials, formulations, functional skincare products, skin health management, and medical services [1]

Core Viewpoint - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (referred to as "Zhonghui Biotech") officially listed on the Hong Kong Stock Exchange, becoming the 9th local listed company in the China Medical City located in Taizhou [1] Company Overview - Zhonghui Biotech focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods [1] - The company has launched a subunit influenza vaccine product and has obtained multiple clinical approval documents for new vaccine drugs, currently conducting clinical trials and new drug applications (NDA) [1] Key Products - One of the core products is the first domestic quadrivalent subunit influenza vaccine, Hui Er Kang Xin, which has significant upgrades over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and low risk of adverse reactions, making it more effective against influenza viruses [1] - Another core product under development is a lyophilized human rabies vaccine (human diploid cells), which is developed using human diploid cells, providing enhanced safety and is expected to be a good alternative to the mainstream Vero cell rabies vaccine [1] - The company completed Phase I clinical trials for the rabies vaccine in October 2024 and plans to start Phase III clinical trials in the third quarter of this year [1] Future Plans - The chairman and general manager of Zhonghui Biotech, An Youcai, stated that the listing is not the end but a new beginning, aiming to deepen the innovation vaccine field, accelerate the clinical and registration processes of core products, expand production and commercialization capabilities, and explore international markets to contribute to global public health [1]

中国医药健康产业股份有限公司 独立董事制度 （2025 年 8 月修订） 第一章 总则 第一条为保证中国医药健康产业股份有限公司（以下简 称"公司"）规范运作，充分发挥独立董事在公司治理中的 作用，促进独立董事尽责履职，更好地维护中小股东利益， 根据《中华人民共和国公司法》 （以下简称"《公司法》" ）《中 华人民共和国证券法》 《上市公司独立董事管理办法》 （以下 简称" 《独立董事管理办法》"） 《上海证券交易所股票上市规 则》《上海证券交易所上市公司自律监管指引第 1 号—规范 运作》及《中国医药健康产业股份有限公司公司章程》（以 下简称"《公司章程》"）的有关规定，制订本制度。 第二条本制度所称独立董事是指不在公司担任除董事 外的其他职务，并与公司及公司主要股东或实际控制人不存 在直接或者间接利害关系，或者其他可能影响其进行独立客 观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、 实际控制人等单位或者个人的影响。 （五）与公司及其控股股东、实际控制人或者其各自的 附属企业有重大业务往来的人员，或者在有重大业务往来的 单位及其控股股东、实际控制人任职的人员； 第三条独立董事对公司及全 ...

中国医药健康产业股份有限公司 对外担保管理制度 （2025 年 8 月修订） 第一章 总则 第一条 为规范中国医药健康产业股份有限公司(以下简称 "公司")对外担保行为，维护投资者利益，有效控制公司对外 担保风险，促进公司健康稳定发展，根据《中华人民共和国公司 法》 （以下简称"《公司法》"） 《中华人民共和国民法典》 （以下简 称"《民法典》" ）《上市公司监管指引第 8 号——上市公司资金往 来、对外担保的监管要求》 《上海证券交易所股票上市规则》 《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》《上 市公司信息披露管理办法》等法律法规、规范性文件以及《中国 医药健康产业股份有限公司章程》 （以下简称" 《公司章程》 "）的 有关规定，制定本制度。 第二条 本制度所称对外担保是指公司以自有资产或信誉为 他人提供的担保，包括公司对控股子公司的担保。担保方式包括 但不限于保证、抵押、质押，具体种类包括但不限于借款担保、 银行开立信用证和银行承兑汇票担保、开具保函的担保、出具具 有实质担保效力的函件等。 本制度所称的"总资产"指公司合并资产负债表列报的资产 总额，"净资产"指公司合并资产负债表列报 ...